published under permission of the Publishing Division of the Massachusetts Medical Society Article commented: Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 20...

The purpose of the present study was to develop stable lyophilized formulation peginterferon alfa-2b which is acquiescent short lyophilization process. evaluates effect buffering components and cryoprotectant(s) on depegylation in combination with Finally, a process identified can produce pharmaceutical form without any during long-term storage. Formulations were analyzed mainly for by HP-size ...

Background Marrow failure and subsequent pancytopenia result from damage or suppression of pluripotent stem cells or progenitor cells, induced by drugs or viral infection. Physiologically, after the age of 65, bone marrow declines by an intrinsic reduction in cells with an increase of fat, displacing until replacement the hematologic tissue. Cytopenia may be severe and clinically significant in...

Milan, Italy Cost-Effectiveness Analysis of Peginterferon Beta-1a in Italian Relapsing-Remitting Multiple Sclerosis Management Iannazzo S,1 Santoni L,2 Saleri C,2 Puma E,2 Vestri G,2 Giuliani L,1 Canonico PL,3 Centonze D4 1SIHS Health Economics Consulting, Torino, Italy; 2Biogen Italia, Milan, Italy; 3Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy; 4Centre ...

background in patients with chronic hepatitis c, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in genotype 1. objectives in turkey, telaprevir has been used since march 2013. we aimed to evaluate resul...

BACKGROUND/AIMS Chronic hepatitis C patients with advanced fibrosis have unsatisfactory sustained virological response (SVR) rates. Few data demonstrating the efficacy of combination therapy in chronic hepatitis C patients with advanced fibrosis in South Korea are available. The purpose of this study was to assess whether the stage of fibrosis impacts the efficacy of combination therapy for chr...

AIM Biochemical and ultrasound investigations in patients with chronic hepatitis C on a 48-week anti-viral regimen. MATERIAL AND METHODS A group of 6 patients, 4 women and 2 men, age range 24-61, were evaluated at the beginning of therapy and compared after 48 weeks of peginterferon alfa-2a and peginterferon alpha-2b regimen at doses established by the National Treatment Program approved by t...

BACKGROUND Peginterferon alfa and ribavirin combination therapy is an effective treatment for many patients with chronic hepatitis C virus (HCV). Reducing the length of treatment may be advantageous. We performed a systematic review and economic evaluation to assess shorter treatment duration of this regimen. METHODS We searched fourteen bibliographic databases (including The Cochrane Library...

OBJECTIVE In treatment-resistant patients with genotype 2 chronic hepatitis C the suitable treatment duration is still unclear. The aims were to investigate extending combination therapy with peginterferon plus ribavirin for genotype 2. METHODS 7 patients infected with genotype 2 at a high viral load and who did not achieve a sustained virological response (SVR) with the first course of 24-we...

We aimed to determine whether neutrophil-to-lymphocyte ratio (NLR) could be a predictor of antiviral response in chronic hepatitis C patients. A total of 602 consecutive patients (genotype 1, n = 263; genotype 2, n = 297; others/unknown, n = 42) receiving response-guided therapy with peginterferon plus ribavirin were recruited. NLR was related to clinical and virological features and to treatme...